FDA Approved Animal Drug Products
Author :
Publisher :
Page : 144 pages
File Size : 30,80 MB
Release : 1998
Category : Veterinary drugs
ISBN :
Author :
Publisher :
Page : 144 pages
File Size : 30,80 MB
Release : 1998
Category : Veterinary drugs
ISBN :
Author :
Publisher :
Page : 20 pages
File Size : 17,16 MB
Release : 1984
Category : Drugs
ISBN :
Accompanied by supplements.
Author : United States. General Accounting Office
Publisher :
Page : 12 pages
File Size : 16,95 MB
Release : 2001
Category : Drugs
ISBN :
Author : National Academies of Sciences, Engineering, and Medicine
Publisher : National Academies Press
Page : 483 pages
File Size : 39,13 MB
Release : 2017-09-28
Category : Medical
ISBN : 0309459575
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author : Food and Drug Administration
Publisher : DrugPatentWatch.com
Page : 1253 pages
File Size : 23,31 MB
Release : 2011
Category : Medical
ISBN : 193489981X
FDA Orange Book 31st Edition - 2011 (Approved Drug Products With Therapeutic Equivalence Evaluations)
Author : Donald O. Beers
Publisher : Wolters Kluwer
Page : 2154 pages
File Size : 45,97 MB
Release : 2013-05-22
Category : Law
ISBN : 1454836091
Completely updated, the new Eighth Edition of Generic and Innovator Drugs: A Guide to FDA Approval Requirements provides indispensable and practical insights into the FDA approval process. Youand’ll find comprehensive coverage of: Abbreviated new drug applications 505(b)(2) new drug applications Delaying approval of competing products FDA approval of biologic drugs No other book can cover the drug approval process as thoroughly, answering important questions like these: What is required to extend the patent of an FDA-approved product? When must a generic manufacturer notify the innovator manufacturer when submitting an ANDA or 505(b)(2) application? When does the FDA delay approvals because of patent claims, and when does it ignore patents? How can one challenge an FDA exclusivity decision? When can a manufacturer safely sell a drug without prior FDA approval? In what circumstances can a generic manufacturer obtain FDA permission to file an ANDA for a variant of an existing drug? When will the FDA waive or reduce prescription drug user fees? How can a company or an individual avoid debarment? What steps are necessary to comply with the FDAand’s Fraud Policy? When and how can a drug company take advantage of FDA accelerated approval procedures? What are the labeling requirements for exporting approved drugs? How have the changes made by the FDA Safety and Innovation Act, including the Prescription Drug User Fee Act, the Generic Drug User Fee Amendments and the Biosimilars User Fee Act, and the Generating Antibiotic Incentives Now Act affected the overall statutory scheme? Generic and Innovator Drugs: A Guide to FDA Approval Requirements, Eighth Edition provides step-by-step guidance of the approval process and expert interpretation of: The Hatch-Waxman Act (Drug Price Competition and Patent Restoration Act) The Medicare Prescription Drug, Improvement, and Modernization Act The Food and Drug Administration Modernization Act The FDA Export Reform and Enhancement Act The Biologics Price Competition and Innovation Act And more! AUTHOR NOTE Donald O. Beersand’ contributions to this publication were completed before he rejoined the Food and Drug Administration. He has had no part in writing and revising this Eighth Edition.
Author :
Publisher :
Page : 16 pages
File Size : 20,70 MB
Release : 1980
Category : Drugs
ISBN :
Accompanied by supplements.
Author : Food and Drug Administration
Publisher : DrugPatentWatch.com
Page : 1039 pages
File Size : 40,67 MB
Release : 2005
Category : Medical
ISBN : 1934899755
FDA Orange Book 25th Edition - 2005 (Approved Drug Products With Therapeutic Equivalence Evaluations)
Author : Institute of Medicine
Publisher : National Academies Press
Page : 442 pages
File Size : 36,51 MB
Release : 2011-04-03
Category : Medical
ISBN : 0309158060
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Author : Food and Drug Administration
Publisher : DrugPatentWatch.com
Page : 1161 pages
File Size : 35,93 MB
Release : 2009
Category : Medical
ISBN : 1934899798
FDA Orange Book 29th Edition - 2009 (Approved Drug Products With Therapeutic Equivalence Evaluations)